Brainshuttle technology is a new delivery mechanism designed to help monoclonal antibodies cross the blood-brain barrier more efficiently. Denali’s drug for Hunter syndrome uses this technology to penetrate the brain. Roche’s experimental anti-amyloid drug trontinemab is the furthest along in Alzheimer’s development. By improving delivery, these shuttles allow for lower doses of medication while achieving higher, more even distribution throughout the brain.